ReviewMini reviews in medicinal chemistry2025
Improving Drug Solubility with Polymer-Drug Conjugation: Recent Insights.
Review in Mini reviews in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor water solubility limits the bioavailability, absorption, and efficacy of many drugs, especially BCS class II and IV compounds. Polymeric drug conjugation (PDC) is a promising strategy to overcome these challenges by chemically linking hydrophobic drugs with hydrophilic polymers via covalent or non-covalent bonds. This enhances aqueous solubility, stability, and bioavailability, leading to improved therapeutic effects and reduced adverse reactions. PDC prolongs drug circulation, ensuring consistent absorption at lower doses. This article focuses on how this strategy can address solubility issues and enhance drug delivery effectiveness, it also brings spotlight to investigate current advancements in the field of polymer drug conjugates. Following a structured approach guided by PRISMA, relevant research on polymeric conjugation strategies were identified by screening literature from PubMed, Scopus, and Google Scholar etc. Key polymers such as PEG, PLGA, HPMA, chitosan, and dextran etc were investigated for their solubility-enhancing capability. Clinical studies validate its success, making it a novel approach to addressing solubility related pharmaceutical challenges.
Indexed as
Identifiers
40965064What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.